Table 1 Baseline demographics, disease and treatment characteristics of patients treated with rituximab 500 mg × 2 or 1000 mg × 2 for all patients in the cohort at baseline and for those with available response data (DAS28-ESR) at 6 months
All patients | Patients with available response data at 6 months* | |||||
|---|---|---|---|---|---|---|
RTX 500 mg × 2 n = 248 | RTX 1000 mg × 2 n = 2625 | P value (t test, chi-square test) | RTX 500 mg × 2 n = 109 | RTX 1000 mg × 2 n = 1385 | P value (t test, chi-square test) | |
Sex,% female | 83.9 % (248) | 80.3 % (2,625) | 0.17 | 88.1 % (109) | 81.2 % (1,125) | 0.08 |
Age, years | 55.2 ± 15.8 (247) | 52.6 ± 12.6 (2,615) | 0.002 | 55.5 ± 15.1 (109) | 51.1 ± 11.8 (1,380) | <0.0001 |
Disease duration, years | 10.5 (5-18) (240) | 8.1 (5-14) (2,360) | 0.02 | 10 (5-16.8) (108) | 7.5 (5.1-12) (1,329) | 0.02 |
RF, % positive | 81.7 % (241) | 81.2 % (2,031) | 0.84 | 83 % (106) | 81.5 % (876) | 0.7 |
Anti-CCP, % positive | 71.3 % (101) | 73.4 % (806) | 0.64 | 68 % (50) | 74.9 % (363) | 0.29 |
Number of prior biologic agents | 0 (0-1) (207) | 1 (0-2) (2,560) | <0.0001 | 0 (0-1) (102) | 1 (0-1) (1,371) | 0.003 |
Anti-TNF-naive (%) | 58 % (207) | 37.5 % (2,560) | <0.0001 | 58.8 % (102) | 37.1 % (1,371) | <0.0001 |
Number of prior DMARDs | 2.6 ± 1.3 (126) | 2.4 ± 1.4 (2,248) | 0.04 | 2.7 ± 1.3 (55) | 2.3 ± 1.1 (1,256) | 0.02 |
Baseline DAS28-ESR | 5.7 ± 1.3 (215) | 6.1 ± 1.3 (2,069) | <0.0001 | 5.9 ± 1.3 (100) | 6.3 ± 1.2 (1,344) | 0.002 |
Baseline HAQ score | 1.6 ± 0.7 (212) | 1.7 ± 0.7 (1,584) | 0.48 | 1.6 ± 0.7 (100) | 1.8 ± 0.7 (695) | 0.001 |
Concomitant medication: | ||||||
– Any DMARD | 72.6 % (248) | 83.1 % (2,625) | <0.0001 | 75.2 % (109) | 87.5 % (1,385) | <0.0001 |
MTX | 46.4 % (248) | 63.4 % (2,625) | <0.0001 | 50.5 % (109) | 75.1 % (1,385) | <0.0001 |
Glucocorticoids | 65.7 % (248) | 59.3 % (2,221) | 0.06 | 71.6 % (109) | 64.7 % (983) | 0.15 |